Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
| Author | |
|---|---|
| Abstract |
:
Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. The longer-term efficacy and safety of PCSK9 inhibition remain undefined. |
| Year of Publication |
:
2014
|
| Journal |
:
Circulation
|
| Volume |
:
129
|
| Issue |
:
2
|
| Number of Pages |
:
234-43
|
| Date Published |
:
2014
|
| ISSN Number |
:
0009-7322
|
| URL |
:
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.113.007012?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI |
:
10.1161/CIRCULATIONAHA.113.007012
|
| Short Title |
:
Circulation
|
| Download citation |
